Research use only. The materials discussed on this page are sold exclusively for in vitro laboratory research. They are not for human or veterinary use, and nothing here is medical advice or a claim of benefit. Animal-model and clinical data are mentioned only as cited published literature.
BPC-157 and TB-500 are the two most-studied research peptides in tissue regeneration and healing. Although they share similar research indications (musculoskeletal repair, angiogenesis, cytoprotection), their mechanisms of action and pharmacological profiles differ significantly. This comparison synthesizes data from the scientific literature to help researchers choose the right compound for their experimental protocol.
The two compounds
- BPC-157 — view the BPC-157 research product page
- TB-500 — view the TB-500 research product page
Comparison table
| Property | BPC-157 | TB-500 |
|---|---|---|
| Molecular origin | Pentadecapeptide derived from gastric juice (partial sequence of BPC protein) | Fragment 17-23 of Thymosin Beta-4 (acetylated) |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 AA) | Ac-LKKTETQ (7 AA) |
| Molecular weight | ≈ 1419.53 g/mol | ≈ 4963 g/mol (full TB-500) / ≈ 889 g/mol (fragment 17-23) |
| Primary mechanism | NO, VEGF, GHRP modulation — systemic cytoprotection | G-actin binding — cell migration and angiogenesis |
| Signaling pathways | FAK-paxillin, eNOS, VEGFR2 | PI3K/Akt, MMP-2, MMP-9 |
| Half-life (reported) | Short (~30 min serum) — reported gastric-pH stability | Long (~2-3 h plasma) |
| Research applications | Tendon lesions, gastric ulcers (in vitro), neuroprotection | Myocardial regeneration, skin healing, ischemia |
| Commercial form | Lyophilized vial | Lyophilized vial |
| Reconstituted stability (4°C) | ~14 days | ~14 days |
| Purity documentation | Batch CoA (HPLC) | Batch CoA (HPLC) |
Research contexts
Literature contexts for BPC-157
Soft tissue regeneration studies (tendons, ligaments), digestive ulcer models, neuroprotection, and in vitro protocols requiring broad-spectrum cytoprotection.
Literature contexts for TB-500
Skin healing studies, post-ischemic cardiac regeneration, endothelial cell migration, and protocols targeting actin dynamics.
Mechanisms of action
BPC-157
BPC-157 modulates endothelial nitric oxide (NO) pathways and stimulates VEGF expression, promoting angiogenesis. It also acts on the FAK-paxillin pathway involved in fibroblast cell adhesion and migration. In vitro studies suggest modulation of the dopaminergic and serotonergic systems.
TB-500
TB-500 (and its active fragment 17-23) binds to G-actin, modulating F-actin polymerization and promoting cell migration. It increases expression of metalloproteinases MMP-2 and MMP-9, essential for matrix remodeling during healing. The PI3K/Akt pathway is also activated, supporting cell survival.
Combined research context
In the literature, BPC-157 and TB-500 are sometimes studied in combination in musculoskeletal regeneration research protocols, with complementary mechanisms (systemic cytoprotection vs local cell migration). Neither molecule is approved for human clinical use by the FDA, EMA, MHRA, or any regulatory agency.
Related research products
Axion Research Peptides supplies research-grade peptides for in vitro use, with a batch certificate of analysis. Browse BPC-157, TB-500 or the full research catalog.
Frequently asked questions
What is the main difference between BPC-157 and TB-500?
BPC-157 is a synthetic pentadecapeptide derived from a gastric protein, acting via systemic modulation (NO, VEGF). TB-500 is a Thymosin Beta-4 fragment that acts locally via actin binding. The mechanisms are distinct and complementary.
Can BPC-157 and TB-500 be combined in a study?
Yes, some preclinical studies explore their combination for healing and regeneration protocols. The rationale is mechanistic: systemic cytoprotection (BPC-157) + local cell migration (TB-500).
Which is more stable once reconstituted?
Both peptides have similar stability (~14 days at 4°C in sterile aqueous solution). BPC-157 is reported to be stable at gastric pH, which has been examined in in vitro gastric-stability models.
Are these peptides approved in the USA or UK?
No. Neither BPC-157 nor TB-500 is approved by the FDA, EMA, or MHRA for human or veterinary clinical use. They are sold exclusively for in vitro scientific research.
Scientific references
- Sikiric P et al., 2018 — BPC-157 review, Curr Pharm Des.
- Goldstein AL et al., 2012 — Thymosin beta-4 wound healing, Ann NY Acad Sci.
Regulatory disclaimer
The peptides discussed in this comparison are not approved by the FDA, EMA, MHRA, or any regulatory agency for human or veterinary clinical use, except where a specific approved product is named (for example, tesamorelin as Egrifta). They are sold by Axion Research Peptides exclusively for in vitro scientific research. This page summarizes published literature and is neither medical advice nor a recommendation for clinical use.
